In this section we discuss GIFTs (Gate-controlled Internal Flawless systems) from the perspective of ELSI—ethical, legal, and social issues. While advances in science and technology have generated substantial benefits to society, they have also, at times, posed significant social and environmental challenges. Therefore, the development and implementation of emerging technologies must be accompanied by prior assessments of their potential impacts from an ELSI perspective. Researchers and stakeholders thus share the responsibility of envisioning a sustainable future, which requires inclusive dialogue among experts and diverse communities.
GIFTs are composed to phospholipids and DNA. Most components, including synthetic lipids and chemically produced DNA strands, raise no inherent ethical concerns. However, the scaffold strand used in DNA origami is derived from M13mp18, a circular single-stranded DNA obtained through infection of Escherichia coli with the M13 bacteriophage. While bacteriophages are not considered fully living organism by many definitions, their propagation requires the infection of E. coli, which are living cells. This introduces questions of ethical significance.
During bacteriophage infection, some E. coli cells may be killed, which can be interpreted as intentionally inducing disease or death in living organisms for the purpose of DNA production. Some may view this as ethically problematic, whereas others regard microbial utilization as ethically permissible and economically indispensable.
From a utilitarian standpoint—commonly invoked in discussions of animal ethics—the moral evaluation hinges on minimizing suffering . Since E. coli are unicellular organisms lacking sentience or the capacity to experience pain, their use is generally deemed ethically acceptable. By contrast, a land ethics perspective, as articulated by Roderick Nash in The Rights of Nature, extends moral consideration to all life forms. From this vantage, the use of E. coli may warrant ethical scrutiny.
Ultimately, the moral status accorded to microorganisms depends on broader philosophical and cultural frameworks. Hence, inclusive societal dialogue is essential to address such questions at the interface of science, ethics, and policy.
The civilian and military applications of emerging technologies are often inseparable, producing what is known as the “dual-use dilemma.” While GIFTs offer promising applications—such as precision drug delivery, molecular robotics, and synthetic cell engineering—they could, in principle, be misappropriated for harmful purposes, including targeted delivery of toxins or bioweapons.
Molecular robot-like GIFTs equipped with DNA nanostructures may also be perceived as “quasi-intelligent” entities responsive to environmental stimuli. This raises concerns about unintended or uncontrolled behaviors that could generate social risks. Although the immediate threat of misuse remains limited due to the nascent stage of the technology, the potential for malicious exploitation may increase as design flexibility expands and implementation progresses. Accordingly, transparency, rigorous ethical review, principles of safe design, and adherence to the framework of Responsible Research and Innovation (RRI) are imperative from the earliest stages of development.
The future implementation of GIFT-based technologies highlights significant regulatory challenges. In medical applications, such as drug delivery, the incorporation of multiple therapeutics within a single liposome may complicate classification under existing regulatory frameworks, such as the Pharmaceuticals and Medical Devices (PMD) Act. Furthermore, inadequate control of nanostructure stability or degradability could lead to body retention or environmental dispersal, warranting regulatory oversight.
Although the present study does not involve genetic modification or genome editing, the DNA origami scaffold strand (M13mp18) contains viral genetic sequences. It is employed solely as a structural element, without transcription or translation. Thus, the research does not fall under the scope of the Cartagena Act or related international treaties. Nevertheless, DNA usage as genetic engineering may lead to public misunderstanding, necessitating proactive dissemination of accurate information and educational initiatives to prevent misconceptions and unwarranted conflict.
Liability in the event of malfunction represents another legal challenge. For instance, if a GIFT-based nanorobot malfunctions in vivo, the attribution of responsibility—whether to the developer, manufacturer, or medical practitioner—would be legally complex. To address such issues, legal and regulatory frameworks must clarify the distribution of responsibility and obligations across both direct and indirect stakeholders. In the longer term, harmonization of national regulations with international standards will be essential to ensure safety, accountability, and public trust.
The societal implementation of GIFTs may present challenges related to medical disparities, environmental impact, and manufacturing accountability.
The unique capability of GIFTs to reversibly connect vesicular pores via DNA strand displacement, thereby enabling controlled transport of biomolecules and therapeutic agents, holds promise for advanced applications such as molecular robots, multi-compartment artificial cells, and multi-drug delivery systems (DDS). However, these innovations are likely to be adopted first in technologically advanced settings, potentially exacerbating global and socioeconomic disparities in healthcare access. Moreover, their resemblance to “artificial life” may provoke cultural or ethical resistance. Achieving social acceptance requires transparency regarding safety, its in vivo behavior, and long-term effects, as well as inclusive public dialogue aimed at building consensus.
At present, GIFTs are constructed from biodegradable materials, minimizing risks of environmental persistence. This distinguishes them from non-degradable pollutants such as microplastics. Nevertheless, future development of highly stable or non-degradable vesicles could introduce significant ecological risks. For example, environmental release may lead to adsorption of hazardous substances, bioaccumulation through food webs, or uptake by endangered species. To mitigate such risks, strict use of biodegradable materials and incorporation of self-degradation mechanisms are essential design principles for safe implementation.
The synthesis of GIFTs employs cholesterol-modified DNA, albeit in minute quantities that pose no known health risks. Nevertheless, given the public association of cholesterol with cardiovascular disease, misperceptions are possible. Additionally, chloroform—used in lipid preparation—is a volatile, toxic, and carcinogenic substance. However, proper handling under fume hoods can ensure product safety. The use of benign solutes such as glucose and trehalose further enhances biocompatibility.
Despite these safeguards, the safety of GIFTs manufactured outside controlled laboratory conditions cannot be guaranteed. Thus, establishing standardized safe materials, preparation methods, and transparent communication of safety protocols is crucial. Such measures are indispensable for ensuring accountability and fostering societal trust in the technology.
[1] M. Kishimoto, “What is ELSI?,” Center for the Study of Co*Design, Osaka University, Apr. 1, 2020. [Online]. Available: https://elsi.osaka-u.ac.jp/what_elsi. [Accessed: Nov. 15, 2024].
[2] J. Bentham, An Introduction to the Principles of Morals and Legislation, 1789. [Online]. Available: https://www.koeblergerhard.de/Fontes/BenthamJeremyMoralsandLegislation1789.pdf. [Accessed: Nov. 15, 2024].
[3] R. F. Nash, The Rights of Nature: A History of Environmental Ethics, 1990, p. 484, ISBN: 93112-5. [Online]. Available: https://doi.org/10.11501/13078037.
[4] Ministry of Agriculture, Forestry and Fisheries of Japan, “What is the Cartagena Act?,” Jul. 2024. [Online]. Available: https://www.maff.go.jp/j/syouan/nouan/carta/about/. [Accessed: Nov. 15, 2024].
[5] NEW ENGLAND Biolabs, “M13mp18 Single-stranded DNA,” 2024. [Online]. Available: https://www.neb.com/ja-jp/products/n4040-m13mp18-single-stranded-dna. [Accessed: Nov. 15, 2024].
[6] National Human Genome Research Institute, “Ethical, Legal and Social Implications Research Program,” Sep. 16, 2024. [Online]. Available: https://www.genome.gov/10001618/the-elsi-research-program/. [Accessed: Nov. 15, 2024].
[7] Ministry of Foreign Affairs of Japan, “Convention on Biological Diversity (CBD),” Nov. 5, 2024. [Online]. Available: https://www.mofa.go.jp/mofaj/gaiko/kankyo/jyoyaku/bio.html. [Accessed: Nov. 15, 2024].
[8] International Conference on Harmonisation, “ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6(R1),” Jun. 10, 1996. [Online]. Available: https://www.pmda.go.jp/files/000156725.pdf. [Accessed: Nov. 15, 2024].
[9] U.S. Department of State, “Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous or Other Gases, and of Bacteriological Methods of Warfare (Geneva Protocol),” 1928. [Online]. Available: https://www.state.gov/t/isn/4784.htm. [Accessed: Nov. 15, 2024].
[10] Ministry of Health, Labour and Welfare of Japan, “Guideline for the Development of Liposome Formulations,” Notification by Director, Office of Evaluation and Licensing, Pharmaceutical and Food Safety Bureau, Mar. 28, 2016. [Online]. Available: https://www.mhlw.go.jp/web/t_doc?dataId=00tc1720&dataType=1&pageNo=1. [Accessed: Nov. 15, 2024].
[11] S. Morishita, M. Kawamura, R. Shihyo, A. Konagaya, and T. Komiya, “Construction of an ‘ELSI Issue Model’ Based on Public Dialogue on Molecular Robots,” Center for the Study of Co*Design, Osaka University, May 31, 2022. [Online]. Available: https://elsi.osaka-u.ac.jp/system/wp-content/uploads/2022/05/ELSI_NOTE_17_2022_220531.pdf. [Accessed: Nov. 15, 2024].
[12] S. Wasti, I. H. Lee, S. Kim, J.-H. Lee, and H. Kim, “Ethical and legal challenges in nanomedical innovations: a scoping review,” Frontiers in Genetics, vol. 14, Article 1163392, 2023. [Online]. Available: https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2023.1163392/full. [Accessed: Nov. 15, 2024].